Search clinical trials for: recombinant activated factor VII

Total 4570 results

Bayer

Completed

EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Taiwan

Hemophilia A

Taiwan
Octagen Corporation
Biomeasure Inc, Ipsen Group

Completed

Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII

Hemophilia A

United States
Bayer

Completed

Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients (OPTIMS)

Haemophilia A

France, Italy
Bayer

Completed

Prophylaxis Versus on Demand Treatment for Children With Hemophilia A

Hemophilia A

China
Bayer

Completed

Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America

Hemophilia A | Blood Coagulation Disorders

Mexico, Venezuela
Bayer

Completed

Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A

Blood Coagulation Disorders | Hematologic Disease

United States, Germany, United Kingdom, Canada
Bayer

Completed

EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS

Hemophilia A

Croatia, Germany, Saudi Arabia, Kazakhstan, Romania, Russian Federation, Slovenia, Bahrain, United Arab Emirates, Bosnia and Herzegovina, Israel, Kuwait, Libyan Arab Jamahiriya, Morocco, Oman, Qatar, Tunisia
Bayer

Completed

Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222

Hemophilia A

Bulgaria
Bayer

Completed

Prophylaxis Versus On-demand Therapy Through Economic Report (POTTER)

Hemophilia A

Italy
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A

Severe Hemophilia A

United States, United Kingdom, Spain, Hong Kong, Israel, New Zealand, Sweden, Australia, Brazil, Japan, Austria, Belgium, Italy, India, Switzerland, Canada, France, Germany, South Africa
Laboratoire français de Fractionnement et de Biotechnologies

Recruiting

A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM (SCOPE HIM)

Hemophilia

United States, Thailand, Malaysia, Mexico, Turkey, South Africa
Laboratoire français de Fractionnement et de Biotechnologies
LFB USA, Inc.

Completed

LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures (PerSept3)

Hemophilia

United States, Ukraine, Mexico, Russian Federation, South Africa, Spain
Fondazione Angelo Bianchi Bonomi
Sintesi Research Srl

Completed

Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET)

Hemophilia A

United States, India, Spain, Argentina, Austria, Brazil, Chile, Egypt, Iran, Islamic Republic of, Italy, Mexico, Saudi Arabia, South Africa, Turkey
rEVO Biologics
Laboratoire français de Fractionnement et de Biotechnologies

Completed

Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors

Hemophilia A With Inhibitors | Hemophilia B With Inhibitors

United States, Bulgaria, Poland, Russian Federation, Belarus, Georgia, Israel, Romania, Ukraine, United Kingdom
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

RIXUBIS PMS India (RIXUBIS PMS)

Hemophilia B

India
Baxalta now part of Shire

Completed

China ADVATE PTP Study

Hemophilia A

China
CSL Behring

Completed

Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A

Congenital Hemophilia A

United States, Austria, Germany, Malaysia, Netherlands, Philippines, Ukraine, Romania, Spain, Australia, France, Georgia, Italy, Lebanon, Poland, Portugal, Switzerland, Thailand, Turkey
Bayer

Completed

Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment (SPINART)

Hemophilia A

United States, Bulgaria, Romania, Argentina
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A (Kids ALONG)

Hemophilia A

United States, Poland, United Kingdom, Netherlands, South Africa, Hong Kong, Australia, Ireland
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Unknown

Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A

Hemophilia A
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A

Hemophilia A

Poland, Belgium, France, Italy, Spain, United States, Australia, Netherlands, New Zealand, Sweden, Germany, Finland, Hungary
CSL Behring

Completed

An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

Hemophilia A

United States, Australia, Austria, Canada, Czech Republic, Germany, Hungary, Italy, Japan, Lebanon, Malaysia, Netherlands, Philippines, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine, United Kingdom
Baxalta now part of Shire

No longer available

Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies

Acquired Hemophilia A

United States
St. James's Hospital, Ireland
Baxter BioScience

Unknown

Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens (PERSONAL)

Severe Haemophilia A

Ireland
AryoGen Pharmed Co.

Completed

rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study

Severe Hemophilia A

Iran, Islamic Republic of
Nanjing Medical University

Unknown

Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia A

Hemophilia A
rEVO Biologics

Completed

A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B (rhFVIIa)

Hemophilia

Netherlands, United States
University College, London

Recruiting

Nebulised Rt-PA for ARDS Due to COVID-19 (PACA)

COVID

United Kingdom
Baxalta now part of Shire

Completed

Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease

Von Willebrand Disease

United States, Germany, United Kingdom, Italy, Austria, Canada
Bioverativ Therapeutics Inc.

Completed

Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A (ASPIRE)

Hemophilia A

United States, Canada, Italy, Australia, Austria, Belgium, Brazil, France, Germany, Hong Kong, India, Ireland, Israel, Japan, Netherlands, New Zealand, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom
Octapharma

Terminated

Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq (PREVAIL)

Hemophilia A

Canada
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

BAX 855 PK-guided Dosing (PROPEL)

Hemophilia A

Spain, United States, Australia, Singapore, Taiwan, Hong Kong, Malaysia, Bulgaria, United Kingdom, Switzerland, Ukraine, Turkey, Italy, Norway, France, Austria, Romania, Sweden, Poland, Germany, Hungary, Israel
Bayer

Completed

Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980

Hemophilia A

United States
Zhengzhou Gensciences Inc
Jiangsu Gensciences lnc.

Completed

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A (RH-107-III02)

Hemophilia A

China
Bayer

Active, not recruiting

Drug Use Investigation of Kovaltry in Hemophilia A Patients

Hemophilia A

Japan
Baxalta now part of Shire

Completed

Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901

Hemophilia A

United States, France, Austria, United Kingdom, Germany, Belgium, Canada, Italy, Sweden
Baxalta now part of Shire

Completed

Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

Hemophilia A | Hemophilia B

Japan, Russian Federation, Spain, United States, Poland, Romania, Serbia, Taiwan, Ukraine
Zhengzhou Gensciences Inc
Haimen Gensciences lnc

Completed

An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

Hemophilia A

China
American Thrombosis and Hemostasis Network
LFB USA, Inc.

Recruiting

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

United States
Baxalta now part of Shire

Completed

Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A

Hemophilia A

United States, Canada, Puerto Rico
Takeda

Completed

A Study of TAK-660 in Surgical Procedures for People With Hemophilia A.

Hemophilia A

Japan
Baxalta now part of Shire

Completed

Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures

Hemophilia A

United States, Spain, Netherlands, United Kingdom, Bulgaria, Lithuania, Russian Federation, Switzerland, Ukraine
Protein Sciences Corporation
Kaiser Permanente

Completed

Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults

Human Influenza

United States
Baxalta now part of Shire

Completed

Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

Hemophilia A

United States, Poland, Slovenia, Greece, Russian Federation, Hungary, Italy, United Kingdom, Czechia, Austria
Oregon Health and Science University
Baxter Healthcare Corporation

Completed

Prospective Biomarkers of Bone Metabolism in Hemophilia A

Hemophilia | Bone Disease

United States
Takeda
Takeda

Completed

ADYNOVATE Drug Use-Results Survey

Hemophilia A

Japan
Bayer

Completed

Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis (TAURUS)

Hemophilia A, Congenital

Slovenia, Italy, Germany, France, United States, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Taiwan
University of Texas Southwestern Medical Center

Recruiting

POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies

Hemophilia A | Factor VIII

United States
Livzon Pharmaceutical Group Inc.

Active, not recruiting

Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (COVID-19)

COVID-19 Pandemic

China
Baxalta now part of Shire

Completed

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

Von Willebrand Disease

Netherlands, Spain, United States, Belgium, Australia, United Kingdom, Austria, Italy, Bulgaria, Japan, Poland, Germany, India, Canada, Russian Federation, Sweden

Search clinical trials for: recombinant activated factor VII

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations